What a pleasure to participate in #ECCO26! 🎉

We were happy to contribute with talks, oral presentations of abstracts, and poster presentations. Associate Professor @sazonovs.bsky.social received the Young Researcher Award 2026 and Assistant Professor Filip Ottosson received the ECCO Grant.

@dg.dk

ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients.
#News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients.
#News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

Tran concludes that additional molecular information provided by the molecular medicine board significantly improved therapy outcomes

#ECCO2026 #ECCO26 #GastroSky #IBDSky

Florian Tran presents results from GUIDE-IBD, a trial using an RNA-based biomarker to inform therapy guidance for patients with IBD initiating infliximab

#ECCO2026 #ECCO26 #GastroSky #IBDSky

📢 ACCU España también ha estado presente en la Conferencia de la IFCCA (Federación Internacional de Enfermedad de Crohn y Colitis Ulcerosa), en el marco de #ECCO26

El tema central fue la HTA (Evaluación de Tecnologías Sanitarias) y la importancia de colocar el paciente en el centro

Just presented at #ECCO2026 - 10-year data from the LIR!C trial comparing ileocaecal resection vs infliximab for ileal Crohn’s disease

Now published in @lancetgastrohep.bsky.social

www.thelancet.com/journals/lan...

#ECCO26 #GastroSky #MedSky #IBDSky

We’re presenting new data at ECCO on how AI is advancing objective assessment in Ulcerative Colitis, from endoscopy to histology.

If you’re attending ECCO, we welcome the discussion.

#Perspectum #ECCO26

Want to connect? We will be at #ECCO26 later this week 👋

#ECCO26 Feb 19 Stockholm, Ludwig Erlmeier (UMCG) presents: “High-throughput antibody epitope repertoire profiling links NOD2 risk-variants to specific antibody responses in Crohn’s disease.”
A step toward connecting genetic risk with functional immune signatures in IBD
cm.ecco-ibd.eu/cmPortal/sea...